Abstract
Purpose
We sought to review outcomes in patients with stage IVB carcinoma of the cervix treated with irradiation in combination with chemotherapy.
Materials and methods
We report outcomes of 24 consecutive patients with good performance status treated from 1998 to 2005. Most of these patients underwent concurrent irradiation with platinum-based chemotherapy. Some patients received subsequent systemic chemotherapy.
Results
All patients underwent external beam radiotherapy; 7 patients (29%) had additional high-dose-rate and 12 (50%) low-dose-rate brachytherapy. Two patients (8%) received an IMRT boost instead of brachytherapy. The mean dose to point A was variable (73.9 ± 19.2 Gy). Twenty patients (83%) received radio-sensitizing platinum-based chemotherapy, and the remaining had radiotherapy alone. Seven patients (29%) had further combination chemotherapy. Therapy was well tolerated. The overall survival was 44% at 36 months and 22% at 5 years.
Conclusion
Patients with stage IVB cervical cancer have mostly been treated with palliative intent. With the advent of concurrent chemoradiation, we have treated many of these cases with aggressive combination therapy. In this series, the use of radiotherapy and multiagent chemotherapy in patients with stage IVB cervical carcinoma and good performance status was well tolerated and resulted in higher survival rates than previously reported.
Similar content being viewed by others
References
Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. (eds). SEER Cancer Statistics Review, 1975–2002. Bethesda, MD: National Cancer Institute. http://cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER web site, 2005
Surveillance Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database. Incidence—SEER 9 Regs Public-Use, November 2004 Sub (1973–2002). Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Released April 2005, based on the November 2004 submission
J Shepherd (1989) ArticleTitleRevised FIGO staging for gynaecological cancer Br J Obstet Gynaecol 96 889–92 Occurrence Handle2775686 Occurrence Handle1:STN:280:BiaA2sritV0%3D
The revised common toxicity criteria: version 2.0. CTEP website (http://ctep.info.nih.gov)
EL Kaplan P Meier (1958) ArticleTitleNonparametric estimation from complete observations J Am Stat Assoc 53 457–81 Occurrence Handle10.2307/2281868
DM Parkin F Bray J Ferlay P Pisani (2005) ArticleTitleGlobal cancer statistics, 2002 CA Cancer J Clin 55 74–108 Occurrence Handle15761078 Occurrence Handle10.3322/canjclin.55.2.74
WJ Spanos TJ Pajak B Emami P Rubin JS Cooper AH Russell et al. (1996) ArticleTitleRadiation palliation of cervical cancer J Natl Cancer Inst Monogr 21 127–30 Occurrence Handle9023842
GM Sommers PW Grigsby CA Perez HM Camel MS Kao AE Galakatos et al. (1989) ArticleTitleOutcome of recurrent cervical carcinoma following definitive irradiation Gynecol Oncol 35 150–5 Occurrence Handle2807004 Occurrence Handle1:STN:280:By%2BD3svjsF0%3D Occurrence Handle10.1016/0090-8258(89)90033-4
T Thigpen R Vance B Lambuth L Balducci T Khansur J Blessing et al. (1987) ArticleTitleChemotherapy for advanced or recurrent gynecologic cancer Cancer 60 2104–16 Occurrence Handle3308070 Occurrence Handle1:STN:280:BieD3c7pslI%3D Occurrence Handle10.1002/1097-0142(19901015)60:8+<2104::AID-CNCR2820601524>3.0.CO;2-D
PG Rose MS Piver JH Malfetano TR Baker RE Hempling FO Recio (1993) ArticleTitleA phase II study of weekly cisplatin followed by cisplatin and ifosfamide in advanced or recurrent cervical carcinoma Cancer 71 2245–9 Occurrence Handle8453545 Occurrence Handle1:STN:280:ByyB3c7ktlE%3D Occurrence Handle10.1002/1097-0142(19930401)71:7<2245::AID-CNCR2820710714>3.0.CO;2-P
JH Edmonson PS Johnson HS Wieand GD Malkasian SA Cullinan LD Brown et al. (1988) ArticleTitlePhase II studies of bleomycin, cyclophosphamide, doxorubicin and cisplatin, and bleomycin and cisplatin in advanced cervical carcinoma Am J Clin Oncol 11 149–51 Occurrence Handle2451883 Occurrence Handle1:STN:280:BieC1M7nvFU%3D Occurrence Handle10.1097/00000421-198804000-00012
EJ Buxton (1992) ArticleTitleExperience with bleomycin, ifosfamide and cisplatin in primary and recurrent cervical cancer Semin Oncol 19 9–17 Occurrence Handle1384148 Occurrence Handle1:STN:280:ByyD3s%2FovFU%3D
MS Piver SA Ghamande GH Eltabbakh C O'Neill-Coppola (1999) ArticleTitleFirst-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix—a phase II study Gynecol Oncol 75 334–7 Occurrence Handle10600285 Occurrence Handle1:CAS:528:DyaK1MXnvFartL4%3D Occurrence Handle10.1006/gyno.1999.5586
G Zannetta F Fei G Parma M Balestrino A Lissoni A Gabriele et al. (1999) ArticleTitlePaclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer Ann Oncol 10 1171–4 Occurrence Handle10.1023/A:1008362814642
PG Rose JA Blessing DM Gershenson R McGehee (1999) ArticleTitlePaclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study J Clin Oncol 17 2676–80 Occurrence Handle10561341 Occurrence Handle1:CAS:528:DyaK1MXmtlWrurc%3D
JP Curtin JA Blessing KD Webster PG Rose AR Mayer WC Fowler SuffixJr et al. (2001) ArticleTitlePaclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study J Clin Oncol 19 1275–8 Occurrence Handle11230468 Occurrence Handle1:CAS:528:DC%2BD3MXit1ert74%3D
HJ Long Suffix3rd S Rayson KC Podratz S Abu-Ghazaleh V Suman LC Hartmann et al. (2002) ArticleTitleLong-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin and cisplatin with or without the addition of molgramostim and review of the literature Am J Clin Oncol 25 547–51 Occurrence Handle12477995 Occurrence Handle10.1097/00000421-200212000-00002
MA Dimopoulos CA Papadimitriou K Sarris G Aravantinos C Kalofonos D Gika et al. (2002) ArticleTitleCombination of ifosfamide, paclitaxel and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group Gynecol Oncol 85 476–82 Occurrence Handle12051877 Occurrence Handle1:CAS:528:DC%2BD38XktlWqtr8%3D Occurrence Handle10.1006/gyno.2002.6649
A Cerrotta G Gardan R Cavina F Raspagliesi B Stafanon I Garassino et al. (2002) ArticleTitleConcurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix: a pilot study with intensification dose Eur J Gynaecol Oncol 23 115–9 Occurrence Handle12013105 Occurrence Handle1:STN:280:DC%2BD383mvFKlsA%3D%3D
I Chitapanarux A Tonusin V Sukthomya C Charuchinda N Pukanhapan V Lorvidhaya (2003) ArticleTitlePhase II clinical study of irinotecan and cisplatin as first-line chemotherapy in metastatic or recurrent cervical cancer Gynecol Oncol 89 402–7 Occurrence Handle12798702 Occurrence Handle1:CAS:528:DC%2BD3sXksVGmsrk%3D Occurrence Handle10.1016/S0090-8258(03)00174-4
DH Moore JA Blessing RP McQuellon HT Thaler D Cella J Benda et al. (2004) ArticleTitlePhase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study J Clin Oncol 22 3113–9 Occurrence Handle15284262 Occurrence Handle1:CAS:528:DC%2BD2cXpsVGrsrk%3D Occurrence Handle10.1200/JCO.2004.04.170
AD Tiersten MJ Selleck DL Hershman D Smith EE Resnik AB Troxel et al. (2004) ArticleTitlePhase II study of topotecan and paclitaxel for recurrent, persistent or metastatic cervical carcinoma Gynecol Oncol 92 635–8 Occurrence Handle14766258 Occurrence Handle1:CAS:528:DC%2BD2cXptV2qtQ%3D%3D Occurrence Handle10.1016/j.ygyno.2003.11.019
HJ Long Suffix3rd BN Bundy EC Grendys SuffixJr JA Benda DS McMeekin J Sorosky et al. (2005) ArticleTitleRandomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study J Clin Oncol 23 4626–33 Occurrence Handle15911865 Occurrence Handle1:CAS:528:DC%2BD2MXotFarsrk%3D Occurrence Handle10.1200/JCO.2005.10.021
S Nagao K Fujiwara T Oda H Ishikawa H Koike H Tanaka et al. (2005) ArticleTitleCombination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer: a pilot study Gynecol Oncol 96 8059 Occurrence Handle10.1016/j.ygyno.2004.11.044 Occurrence Handle1:CAS:528:DC%2BD2MXhsVOjs7g%3D
JA Green JM Kirwan JF Tierney P Symonds L Fresco M Collingwood et al. (2001) ArticleTitleSurvival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis Lancet 358 781–6 Occurrence Handle11564482 Occurrence Handle1:STN:280:DC%2BD3MrhslOgtA%3D%3D Occurrence Handle10.1016/S0140-6736(01)05965-7
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was presented at the 37th annual meeting of the Society of Gynecologic Oncologists, Palm Springs, CA, March 2006
About this article
Cite this article
Zighelboim, I., Taylor, N., Powell, M. et al. Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy. Radiat Med 24, 625–630 (2006). https://doi.org/10.1007/s11604-006-0082-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11604-006-0082-6